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ABSTRACT  
Prostate cancer (PC) is the most widespread form of cancer among men in Sweden, with 
an annual incidence of approximately 10,000 new cases. Treatment of localized prostate 
cancer is controversial. Curative intended treatments for localized disease include radical 
prostatectomy (RP) and radiotherapy (RT). These treatments considered to be equally 
effective, but have different side effects. ADT commonly used as neo-adjuvant therapy in 
curative intended radiotherapy. The various regimens of ADT have different side effect 
profiles. Thus, patients need information about how the different side effects might 
influence their health-related quality of life (HRQoL), both concering primary treatment 
(RP and RT) and about ADT. 
 
Providing adequate information to cancer patients facilitate their adjustment to the cancer 
experience by increasing perceptions of control, reducing feelings of threat and anxiety, 
and in improving HRQoL.Thus, it is of importance to investigate satisfaction with 
information in prostate cancer patients treated with curative intention. 
 
The aims of Paper 1, were to compare information perception and satisfaction with that  
and influence on HRQoL in patients primarily treated with RT alone or with salvage RT after 
failure of RP. Using the EORTC QLQ C-30 and EORTC INFO 25 questionnaires in 660 
patients prospectively. Higher levels of satisfaction with information and more favorable 
HRQoL were found in patients treated with RT primarily compared to surgery + salvage RT.  
 
In Paper 2, the aims were to compare HRQoL of RT and RP in a randomized trial of 89 
patients in curative setting. EORTC QLQ C-33 questionnaire and 20 specific questions 
were asked by mailed questionnaires. No differences between the two treatments were 
found. It was not possible to draw any conclusion about efficacy of the treatments due to 
insufficient power of the study.  
 
In Paper 3, the aims were to compare differences in HRQoL after randomizing anti-
androgen versus total androgen blockade in 110 curative intent RT patients. EORTC 
QLQ C-30 and EORTC QLQ PR25 were used. Statistically significant differences in 
sexual interest and function were noted, in favour of anti-androgen treated patients. In 
addition, higher levels of overall quality of life and sexual interest as well as lower levels 
of fatigue, and urinary problems were found at the three-months assessment in the anti-
androgen group compared to the total androgen blockade group. The difference in sexual 
interest remained to the 18-months assessment. At that point of time, significant difference 
favoring the anti-androgen group found in cognitive functioning. 
 
In Paper 4, the aims were to compare differences in changes of prostate volume and in 
target volume in patients included in Paper 3. Ultrasound technique was used to 
investigate differences in PV after neo-adjuvant hormonal therapy according to 
randomization arm. Total androgen blockade was more effective in decreasing PV. This 
effect was translated to target volume. PV increased during treatment in a few patients in 
both groups. 
 
Conclusion: Information is important for PC patients´ HRQoL and there is room for 
improvement, especially for men who are about to receive salvage radiotherapy. No 
differences in HRQoL were found between PC patients treated with RP or RT. The study 
was, however, underpowered. Anti-androgen treatment resulted in better HRQoL in the 
short run as compared to total androgen blockade. Largest effects were noted in the 
sexual area. Total androgen blockade had a better effect on decreasing prostate volume. 
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1 INTRODUCTION  
 
Prostate cancer (PC) is the most common cancer among Swedish men (Socialstyrelsen, 
2015). The incidence has increased over the last decades in the western world (Nilsson et al., 
2004). The introduction of PSA testing has led to an increasing proportion of patients 
presenting with localised disease (Dearnaley et al., 2007). PC commonly affects men with 
high age. Other concurrent illnesses play role in treatment modalities chosen and for survival. 
The disease is for some patients aggressive at diagnosis, but for the majority, the expected 
survival time is long. The optimal treatment today for localized PC is a matter of debate 
(Nilsson et al., 2004; Dearnaley et al., 2007). Radical prostatectomy (RP) and radiotherapy 
(RT) are the most commonly used curative options at this stage. Both treatments are 
associated with side effects influencing health-related quality of life (HRQoL). Active 
surveillance and watchful waiting are other options for selected patients. Information 
regarding HRQoL is of utmost importance, as these modalities have different profiles of side 
effects and may affect the choice of treatment option. 
In this thesis, patient reported outcomes regarding HRQoL, genitourinary, gastrointestinal 
and sexual problems highlighted in the context of curative intent RT in localized PC patients. 
In addition, patients’ evaluation of information given during PC treatment been studied. 
Focus has also been on hormonal influence on prostate volume in the neo-adjuvant setting, 
and to side effects after radiotherapy with curative intent. Patient reported outcomes are the 
mainstay in our work, by using different EORTC (European Organization for Research and 
Treatment of Cancer)-questionnaires. The results of our studies may be supportive in PC-
treatment decision-making consultations.
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2 PROSTATE CANCER, TREATMENT AND HEALTH-
RELATED QUALITY OF LIFE 
 
2.1 EPIDEMIOLOGY 
 
According to WHO there were 14.1 million new cancer cases, 8.2 million cancer deaths 
and 32.6 million people living with cancer (within 5 years of diagnosis) worldwide in 
2012 (WHO, GLOBOCAN, 2012). PC is the second most common cancer in men. An 
estimated 1.1 million men worldwide were diagnosed with PC in 2012, accounting for 
15% of the cancers diagnosed in men, with almost 70% of the cases (759 000) occurring 
in more developed regions. PC incidence varies more than 25-fold worldwide. The rates 
are highest in Australia/New Zealand and Northern America together with Western and 
Northern Europe, because of prostate specific antigen (PSA) testing and subsequent 
biopsy has become widespread in those regions. Age Standardised Ratio (ASR) varies 
between 97 -226/100,000. Incidence rates are also relatively high in certain less 
developed regions such as the Caribbean (80), Southern Africa (62) and South America 
(60), but remain low in Asian populations with estimated rates of 10.5 and 4.5 in 
Eastern and South-Central Asia respectively. 
 
With an estimated 307,000 deaths in 2012, PC is the fifth leading cause of death from 
cancer in men (6.6% of total men deaths). Because PSA testing has a much greater 
effect on incidence than on mortality, there is less variation in mortality rates worldwide 
(ten-fold from approximately 3 to 30 per 100,000) than observed for incidence, with the 
number of deaths from PC larger in less developed regions than in more developed ones 
(165,000 compared to 142,000, respectively). Mortality rates are generally high in 
predominantly black populations (Caribbean, 29 per 100,000 and sub-Saharan Africa, 
ASRs 19-24 per 100,000), very low in Asia (2.9 per 100,000 in South-Central Asia for 
example) and intermediate in the Americas and Oceania (Australia/South East 
Asia/Malay Archipelago/parts of USA). 
 
In Sweden, PC accounts for around 10,000 new cases in each year (Socialstyrelsen, 
2015).  PC constitutes over 30% of all malignancy in men in Sweden. Median age at 
diagnosis is >70 years. The average annual increase is 1.4 % over the last 20 years. The 
introduction of PSA testing partly explains the large increase in the late 1990s’ and 
early 2000s’, but the incidence appears to decrease during the last few years 
(Socialstyrelsen, 2015). There is an 80% risk of dying of PC if diagnosed before 60 years 
of age, 63% if diagnosed between 60 and 69 years, 53% för ages 70 and 79 years, and a 
49% risk for ages 80 and over (Grönberg, 1997).  
 
2.2 ETIOLOGY 
The actual cause of PC is still unknown, but several factors associated with the risk of PC 
development, have been identified: 
Age: Aging is the most significant risk factor for PC (Abate-Shen & Shen, 2000). The 
mean age at diagnosis in Sweden is 72–74 years, and about 85% of patients are 
diagnosed after 65 years of age (Grönberg, 2003).    
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Race and ethnicity: Afro-Americans have the highest recorded incidence, almost 
double the risk that of white Americans. Race and age of onset contribute independently 
to hereditary PC (Mydlo & Godec, 2003) and similar findings been observed in men in 
the Caribbean (Mallick et al., 2005). Higher incidence rates also observed in Uganda 
(Wabinga et al., 2000) and in Nigeria (Ogunbiyi & Shittu., 1999). In contrast, the 
incidence appears to be lower among Chinese and Japanese men. Japanese migrants to 
US, however, shown to have a higher incidence compared to men still living in Japan 
(Shimizu et al., 1991). These variations suggest that the risk for PC has a genetic 
component, and that lifestyle factors may play an important role. One study showed 
remarkable improvements in pathologic stages in Afro-American men after retropubic 
RP where pT3 disease minimized from 100% to 35%, whereas it decreased from 57% to 
43% in white Americans (Paquette et al., 2001). Positive margins decreased from 100% 
to 26%, and 41% to 27% respectively. The authors concluded that equal availability of 
screening and PSA testing between both races made those differences. 
 
Family history: Familial PC is commonly defined as a family in which there are two 
first-degree relatives (father, brother, son), or one first-degree and at least two second-
degree relatives (grandfather, uncle, nephew, half brother) with PC (Stanford & 
Ostrander et al., 2001). A subset of familial PC is considered to be hereditary, defined 
by at least one of following criteria: 1) three or more first-degree relatives with PC; 2) 
three successive generations with PC, either through paternal or maternal lineage; or 3) 
two siblings with PC diagnosed at a relatively young age (e.g., <55 years). It estimated 
that hereditary PC might account for 5-10% of all cases of PC in the general population 
(Stanford & Ostrander et al., 2001; Karayi et al., 2004).  
 
Gene changes: Several inherited genes that seem to raise PC risk have identified. In a 
meta-analysis of RNASEL (Ribonuclease L) polymorphisms, no corelation with overall 
PCa risk found. In subgroup analyses, however, a low-penetrent risk gene for sporadic 
PCa found (Wei et al., 2012). Tumour suppressor genes BRCA 1 and BRCA 2 are 
active in DNA repair. Inherited mutations in these genes more commonly cause breast 
and ovarian cancer in women, but also account for a very small number of PCs 
(Thompson et al., 2001; 2002). Inherited mutations in DNA mismatch repair genes 
MSH2 and MLH1 give rise to Lynch syndrome, and individuals´ cumulative lifetime 
risk of PC with this syndrome are two-fold higher than for the general population 
(Raymond et al., 2011). A case-control study showed a strong link between loss of the 
Y-chromosome and male carcinogenesis like coloncancer and PC (Noveski et al., 2016).  
Diet: The exact role of diet in PC is not clear, although a number of factors had been 
studied. Dietary intake of tomatoes and tomato products, containing lycopene and 
carotenoids, has shown to be inversely associated with the risk of PC (Basu et al., 
2007). A high intake of protein or calcium from dairy products suggested increasing the 
risk for PC (Allen et al., 2008). Several studies have reported associations between fat 
consumption and PC mortality, supporting the hypothesis of an increased risk in men 
who consume larger total calories as fat (Boyle et al., 1995).  Other studies have shown 
an increased risk with saturated fat, specifically with high intake of processed red meat 
(Rodriguez et al., 2006; Rohrmann et al., 2007). 
Obesity: Obesity appears be linked to aggressive PC (Allot et al., 2013). Excess adipose 
tissue generates a state of systemic inflammation and mediates steroid hormone 
metabolism, insulin sensitivity and cytokine release (Fowke et al., 2015). Other studies 
have suggested that a higher BMI is associated with PC mortality (Andersson et al., 
1997; Kane et al., 2005), biochemical failure after treatment (Strom et al., 2005; Bassett 
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et al., 2005) and diagnosis of advanced PC (MacInnis et al., 2006; Gong et al., 2006). 
 
Smoking and alcohol: A positive association between moderate alcohol consumption 
and the risk of PC has been demonstrated (Sesso et al., 2001). Liquor, but not wine or 
beer, consumption, was associated with increased PC risk. In a retrospective study of 
8,190 men, current smokers were more likely to have acute prostatic inflammation than 
former and never smokers (Moreira et al., 2015). In another, prospective trial of more 
than 16,000 men, a decreased risk of diagnosed with PC found in current and former 
smokers, but current smokers were at an increased risk of dying from PC (Watters et al., 
2009). 
 
Environmental and occupational factors: A large Swedish study has shown an 
increased risk of PC in pesticide workers (Dich & Wiklund, 1998). In addition, men 
exposed to cadmium and those working in the nuclear power industry have found to 
have an increased risk of PC (Kirby & Brawer, 2004). 
 
2.3 HORMONAL REGULATION 
 
The prostate is regulated by androgens, and thereby dependent on androgens for 
development, growth, and maintenance of size and function (Hayward & Cunha, 2000). 
Testosterone is the main androgen in males and produced by leydig cells in the testes. 
Production of testosterone stimulated by the hypothalamus through luteinising hormone 
releasing hormone (LHRH) that activates the pituitary gland in anterior hypophysis to 
produce luteinising hormone (LH), which in turn stimulates the leydig cells. There is 
also a negative feedback loop where testosterone inhibits the release of LHRH. 
Testosterone converted in the prostate by 5-alfa-reductase to dihydrotestosterone, which 
is a more potent androgen (Krieg et al., 1995). Androgens are important in the 
development and maintenance of sexual function, and androgen stimulation plays a 
central role in the development of PC (Wu & Gu, 1991). Three distinct phenotypes in 
PC have postulated: androgen-dependent, androgen-sensitive, and androgen-
independent. Androgen-dependent cancer cells require androgenic stimulation for their 
growth, without which they die (Isaacs et al., 1992). In contrast, androgen-sensitive 
cancer cells do not die, even if no androgen is present. Growth rate however decreases 
following androgen ablation. Androgen-independent cancer cells are completely 
autonomous to androgenic effects (DeVita et al., 1997). 
2.4 DIAGNOSIS 
Triple diagnostics, including prostate-specific antigen (PSA)-test, core biopsy, and digital 
rectal examination (DRE), is the recommended way to diagnose PC. 
2.4.1 Prostate-specific antigen (PSA) 
 
Prostate-specific antigen is an enzyme found in men without disease. PSA is a protease 
that keeps semen liquid (Neal et al., 1992; Nickel, 1999). The PSA level in prostatic 
fluid is approximately one million fold higher than that found in the serum. An 
  6 
epithelial layer, a basal cell layer, and a basement membrane separate the intraductal 
PSA from the capillary and lymphatic drainage of the prostate (Brawer, 2008). 
Malignancy or inflammation in prostate interferes with this natural barrier; it believed 
the leakage of PSA into the serum causing an elevated PSA (Brawer, 2008). PSA is 
considered the best tumour maker for PC in serum analysis, but the specificity of serum 
PSA is low (Sardana et al, 2008). On the other hand, however, tissue expression of PSA 
is highly specific for prostate tissue (Sardana et al., 2008). There is a decreased PSA 
immunoreactivity in adenocarcinomas with higher Gleason scores, whereas all with a 
Gleason score six or seven were reactive for PSA (Goldstein, 2002). Selection of PSA 
cutoffs depends on the physicians’ view of sensitivity-specificity tradeoffs. For PSA of 
>4 ng/ml, there is a 1 in 3 chances of finding cancer, regardless of patient age (Catalona 
et al., 1996). Biopsy detected PC including high-grade cancers is not rare with a PSA 
upto 4.0 ng/ml, level usually considered as normal (Thompson et al., 2004). PSA tends 
to rise with age, might be due to BPH-growth in transitional zone or deterioration of 
glandular structure in elderly prostate, facilitating more PSA to leak back into the 
circulation (Berry et al., 1984). Due to these above reasons, a cut-off 4.0 ng/ml, to some 
extent not logical (Shaida & Malone, 2008). 
2.4.2 Digital rectal examination (DRE) 
DRE is the standard way to define texture, shape, size and tenderness of the prostate 
gland. It is simple and virtually complication-free, but dependent on the examiner and 
therefore subjective (Varenhorst et al., 1993). DRE is less effective than PSA in finding 
PC but cancers in men with normal PSA levels sometimes found (American Cancer 
Society, 2015). DRE is limited because the procedure only allows palpating the 
posterior surface of the gland. Men with abnormal DRE should therefore proceed to 
core biopsy regardless of PSA value (Dunn & Kazer, 2011).      
   
   Figure 2: Digital Rectal Examination                                                                             
(Reprinted with permission from WebMD Corporation). 
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2.4.3 Core biopsy 
 
The clinical judgement and recommendation to proceed with a prostate biopsy depends 
on risk factors, such as PSA, DRE, a positive family history of PC, age, previous 
prostate biopsy, as well as the patient's life expectancy (Foley et al., 2016). EAU 
guidelines (2011) recommended 10 cores as a minimum. Saturation biopsy protocols (at 
least 20 cores) are occasionally used and regarded as a valuable tool by some authors 
(Ravery et al, 2008; Pal et al., 2012), but others claim that there is little increase in 
detection rate (Eichler et al, 2006). However, the probability of missing a cancer with 
prostate biopsy under TRUS guidance estimated at 25 %, even with saturation biopsies 
(Aganovic et al, 2011; Shariat, 2011). Transperineal Template Prostate Biopsy (TPTPB) 
is a technique that has gained more popularity over the last decade. A study assessed 
TPTPB in the initial and repeated biopsy setting, and found high rates of cancer 
detection (80%) in biopsy naı¨ve men, and with a rate of 46.9 % as a repeat biopsy 
(Taira et al. 2010). This partly been attributed to the fact that TPTPB detects, in 
particular, tumours located in the apical and anterior zones of the prostate, often poorly 
sampled by TRUS biopsy (Mabjeesh et al 2012; Dimmen et al, 2012). 
 
2.4.4 Transrectal ultrasound (TRUS) 
 
TRUS with rectal probe is being used to define prostate gland and for assistance during 
core biopsy. Low echogenicity usully give rise to the suspicion of cancer, confirmed by 
core biopsy. Today, Magnetic Resonance Imaging (MRI) is widely used to improve the 
diagnostic sensitivity of prostate biopsy (Toner et al., 2015).  Prostate volume can be 
assessed by various methods, of which the most commonly used in TRUS is the 
ellipsoid formula (height*width*length*π/6) (Terris & Stamey, 1991; Bangma et al., 
1996; Kälkner et al., 2006).  
Histopathology 
PC can be divided into tumors derived from the epithelial component and the 
nonepithelial/stromal component. The epithelial derived tumors further subdivided into 
the most common morphologic appearance to acinar, comprising 90% of tumors and 
have variants such as microacinar, atrophic, pseudohyperplastic, and signet ring 
(Glaessgen, 2008). The non-acinar group includes ductal, sarcomatoid, and small cell 
carcinoma, as well as urothelial carcinoma. The rarer nonepithelial/stromal tumors 
occurring in the prostate include leiomyosarcomas and solitary fibrous tumors 
(Humphrey, 2012). 
A prospective diagnostic study, aimed to increase the specificity compared to PSA in 
Swedish men aged between 50 and 69 years, was recently published (Grönberg et al., 
2015). A predefined STHLM3 model bloodtest was used, consisting of a combination 
of plasma protein biomarkers as PSA, free PSA, intact PSA, hK2, MSMB, MIC1, 
genetic polymorphisms [232 SNPs], and also including clinical variables such as age, 
family history, previous prostate biopsy and prostate examination. The STHLM3 model 
performed significantly better than PSA alone for detection of cancers with a Gleason 
score of at least 7. PSA test using a cutoff of ≥3 ng/mL to diagnose high-risk prostate 
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cancer and the use of the STHLM3 model is estimated to reduce the number of biopsies 
by 32% and would avoid 44% of benign biopsies. 
 
The WHO grading system (WHO, 1980) was previously the standard for grading 
prostate adenocarcinoma histopathologically. The Gleason grading system, using core 
biopsy-results, has becoming more and more popular since the 1990´s (Gleason & 
Mellinger, 1974; Gleason 1992). 
The WHO grading system 
The WHO grading system is a cytological grading system, where PC tumours are 
divided into three grades (G1-3 = well, moderately or poorly differentiated), based on 
glandular differentiation and nuclear pattern (WHO. Geneva 1980). 
 
The Gleason grading system 
WHO recommends the Gleason score (GS) as the official grading system in PC with 
core biopsy, where one can expect more prognostic information than from cytological 
grading (Eble, 2004; Roach et al., 1999). The Gleason grading system was developed 
between 1960 and 1974 by reviewing an accumulated number of around 5000 PC 
patients in randomized clinical trials (Bailar et al., 1966; Gleason 1966; Gleason & 
Mellinger, 1974; Gleason, 1992). Extent of glandular differentiation and growth 
patterns are analysed microscopically resulting into 1-5 patterns. The primary and 
secondary pattern, i.e the most prevalent and second most prevalent pattern are added to 
get a GS or sum (GS=Gleason pattern 1 + Gleason pattern 2). The score can range from 
2-10. If the tumour has only one pattern, the GS obtained by doubling that pattern. In 
daily practice a cut-off at 5% often used for inclusion in the GS (Glaessgen, 2008). 
Numerous studies shown that GS is an independent and very powerful prognostic factor 
for prediction of natural history of PC (Albertsen et al., 1995; Egevad et al., 2002a; 
2002b; Andren et al., 2006; Berney et al., 2007).  GS used for assessment of risk for 
recurrence after RP (Epstein et al., 1996; Han et al., 2001; Hull et al., 2002; Han et al., 
2003) or radiotherapy (Zagars et al., 1995; Green et al., 1998).  
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Figure 3. Gleason Grading differentiation. 
2.4.5 TNM classification  
TNM classification is used for staging of PC according to The International Union 
Against Cancer (Leslie et al., 2009), Table 1. 
Table 1. Tumour Node Metastasis (TNM) classification according to UICC (Leslie et 
al., 2009). 
T-primary tumour 
TX            Primary tumour cannot be assessed. 
T0             No evidence of primary tumour. 
T1             Clinically unapparent tumour not palpable or visible by imaging. 
              T1a - Tumour incidental histological finding in 5% or less of tissue resected. 
              T1b-Tumour incidental histological finding in more than 5% of tissue resected                                                                          
              T1c – Tumour identified by needle biopsy (e.g. because of elevated prostate    
                             specific antigen, PSA level) 
T2          Tumour confined within the prostate1. 
               T2a – Tumour involves one half of one lobe or less. 
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                T2b – Tumour involves more than half of one lobe, but not both lobes. 
                T2c - Tumour involves both lobes 
T3            Tumour extends through the prostate capsule2. 
                 T3a – Extracapsular extension (unilateral or bilateral) including microscopic    
                              bladder neck involvement. 
                 T3b –Tumour invades seminal vesicle(s) 
  T4               Tumour is fixed or invades adjacent structures other than seminal vesicles:  
                      external sphincter, rectum, levator muscles, and/or pelvic wall 
  N – Regional lymph nodes3 
                                 NX - Regional lymph nodes cannot be assessed 
                        N0 - No regional lymph node metastasis 
                         N1 – Regional lymph node metastasis 
   M – Distant meatastsis4       
                                     MX - Distant metastasis cannot be assessed 
                         M0 – No distant metastasis 
                         M1 – Distant metastasis 
                                   M1a - Non-regional lymph node(s) 
                                   M1b – Bone(s) 
                                   M1c – Other site(s) 
1 Tumour found in one or both lobes by needle biopsy, but not palpable or visible by 
imaging, is classified as T1c. 
2 Invasion into the prostate apex, or into (but not beyond) the prostate capsule, is not 
classified as pT3, but as pT2. 
3 Metastasis no larger than 0, 2 cm can be designated pN1 mi. 
4 When more than one site of metastasis is present, the most advanced category should 
be used. 
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2.5 PROGNOSIS 
 
Prognosis prediction in tumour pathology is one of the greatest challenges (Burke et al., 
2005). Despite attempts to introduce new biomarkers, histopathological grading remains 
the most important tissue-based predictor of prognosis for PC (Albertsen et al., 1995; 
Glaessgen, 2008). The clinical course of PC is highly variable. Prognosis and survival is 
largely dependent on stage, PSA and histological grading (Mikuz 1997; Oesterling 
1991; Partin et al., 1997). In many men cancer will remain clinically insignificant and 
asymptomatic several years after diagnosis (Chodak et al., 1994; Johansson et al., 
1997). Although the prognostic value of PSA is limited, measurement of the proportion 
of free PSA has improved the identification of patients with aggressive disease 
(Stenman et al., 2005). Furthermore, the rate of increase in serum PSA reflects tumour 
growth rate and prognosis (Stenman et al., 2005). Algorithms based on the combined 
use of free and total PSA and prostate volume in logistic regression can improve the 
diagnostic accuracy for prostate cancer, and other new markers may provide additional 
prognostic information (Stenman et al., 2005). Nomograms often used to predict 
biochemical recurrence-free survival (BRFS) for the different treatment modalities 
available and to aid in treatment selection (Zelefsky et al., 2007; Stephenson et al., 
2006; Potters et al., 2010). However, as the definitions of BRFS differ across the 
various treatments, the ability of these nomograms to correlate BRFS appropriately with 
the more important endpoint of PC-specific mortality among different treatments 
remains unclear (Simon et al., 2015). 
 
 
2.6 TREATMENT OF PROSTATE CANCER 
Curative intended treatments for PC are surgery and radiotherapy. Other strategies, like 
Active Surveillance or Watchful Waiting are appropriate for some patients. 
2.6.1 Surgery  
There are four main types of radical prostatectomy (RP): Open retropubic prostatectomy, 
open perineal prostatectomy, laparoscopic prostatectomy, and robot-assisted 
laparoscopic prostatectomy. Salvage RP is an option for highly selected ptients with 
local recurrence after EBRT or Brachytherapy (BT) in absence of metastasis. 
Open radical prostatectomy: This has been the most common surgical procedure with 
retropubic approach, but however, since 2005 it has been estimated that >75% of RPs 
performed using the da Vinci platform (Mottrie & Ficarra 2010; Mottrie et al., 2011). 
 
Open perineal prostatectomy: This method used less frequently than the retropubic 
approach. This is because the nerves can't be spared easily, nor lymph-nodes be 
removed by using this surgical technique. However, this procedure takes less time and 
may be an option if nerve-sparing approach or lymph-node dissection aren't needed. In 
cosmetic point of view, the retropubic approach is better with a smaller incision. 
Laparoscopic radical prostatectomy. Several small cuts needed to make to place the 
tools and a laparoscope placed inside through one of the cuts. This helps to gain a wider 
perspective inside. 
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Robotic-assisted radical prostatectomy. Laparoscopic surgery in this method uses a 
robotic system. It allows a more precise response and can be performed routinely with a 
relatively small risk of complications. Surgical experience, clinical patient 
characteristics, and cancer characteristics may affect the risk of complications. Blood 
loss and transfusion rates are usually significantly lower with this procedure than with 
laparoscopic method (Novara et al., 2012). 
 
Nerve-sparing procedures represent the approach of choice in all men with normal 
erectile function and organ-confined disease. Robot-assisted laparoscopic technique is 
the gold standard surgical approach for clinically localized PCa in the United States and 
increasingly used in Europe (Novara et al., 2012). High BMI, large prostate volume, 
prior abdominal surgery, prior BPH (Benign Prostate Hyperplasia) surgery, or presence 
of median lobe may make the surgical procedure more difficult, possibly increasing 
operative time, blood loss, or catheterization time (Novara et al., 2012). 
 
2.6.2 Radiotherapy  
 
Three-dimensional conformal RT (3D-CRT) remains the gold standard in external-beam 
RT (EBRT) in many countries and institutions. However, image-guided RT (IGRT) and 
intensity-modulated RT (IMRT), which is an optimized form of 3D-CRT using 
implanted markers in the prostate, should become the standard treatment of choice 
(Bauman et al., 2012). 3D-CRT is a technique where the beams of radiation used in 
treatment shaped to match the tumour. 3D dose planning systems and treatment 
accelerators equipped with multi-leaf collimators have made 3D-CRT possible 
(Lennernäs et al., 1995). Compared to EBRT, this method uses 40-50% lesser volume 
of normal tissue in high-dose region during treatment of PC and feasibility study 
showed greater reduction in gastro-intestinal (GI) toxicity compared to those of EBRT 
(Dearnaley et al., 1999).  
 
RT and androgen suppression: The rationale in combining androgen suppression with 
RT are to decrease prostate volume, reducing local relapse-risk within irradiated area, 
decreasing risk of distant metastases, improving the effectiveness of radiation (Bolla et 
al., 2012). Animal studies have shown that neoadjuvant ADT provides the greatest 
effect according to TCD 50, an apoptotic response and result in prolonged suppression 
of tumor growth ( Zietman et al., 1997; Kaminski et al., 2003, Bolla et al., 2012).  
 
Dose-escalated EBRT: Radiation doses of 64-70 Gy, not as effective as previously 
believed in the treatment of localized PC (Peeters et al., 2006). Dose-escalation has been 
possible with 3D-CRT. Studies showed improved freedom from failure (FFF) at the 
expense of increased overall GI-toxicity (Pollack et al., 2002; Zietman et al., 2005). 
However, in another randomized study, authors found a significant improved FFF using 
higher radiation dose of 78 Gy (Peeters et al., 2006). Higher cure rates seen with 
increasing doses and patients with high risk features seem to benefit most from dose 
escalation (Nilsson et al., 2004). Dose escalation did not result in significant 
deterioration of quality of life (Al-Mamgani et al., 2011). Hypofractionated RT, with 
high biologic effective dose using CRT, found to be well tolerated with minimal severe 
acute toxicity, compared with conventional RT (Viani et al., 2013). 
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Intensity modulated radiation therapy (IMRT) is a method of radiation technique 
where little beamlets of varying intensity occur after division of the beam. This method 
allows delivering required doses to target volumes while sparing normal structures. The 
introduction of IMRT or later developments volumetric modulated arc therapy (VMAT) 
or Rapid Arc, made it possible to treat targets like lymph node volumes, prostate with 
seminal vesicles (Lennernäs et al., 2011). Use of IMRT compared to CRT associated 
with less GI-morbidity and fewer hip-fractures but more erectile dysfunction; IMRT 
compared to proton therapy associated with less GI-morbidity (Sheets et al., 2012). 
 
Brachytherapy (BT) is a specilized form of RT that entails the placement of an 
emitting radiation source (most commonly a radioactive isotope) in immediate 
proximity to macroscopic tumour. BT considered the ultimate form of conformal RT 
because it is unparalleled in its ability to direct a large dose of radiation to the tumour 
while minimizing exposure to surrounding sensitive normal structures (Petereit et al., 
2015). BT offered using low-dose-rate (LDR) or high-dose-rate (HDR) techniques. 
Palladium-103 or Iodine-125 are radioactive sources used in LDR. These sources 
permanently placed in the prostate, whereas Iridium-192 used in HDR technique is 
temporary. BT usually performed using spinal or general anesthesia, where LDR 
delivered as a one-day procedure and HDR with overnight stay at the hospital with a 
urinary catheter. External beam radiotherapy combined with brachytherapy is used 
depending on stage of PC. 
Permanent brachytherapy (seeds): In this LDR-BT, radioisotope placed in the prostate 
permanently where 103Paladium or 125Iodine usually used as source. This treatment 
offered alone or in combination with EBRT. Since the energy of the implanted sources 
is low, the radiation exposure surrounding the patient is low. With 125 Iodine source, a 
dose of 145 Gy achieved whereas with 103Paladium, 125 Gy achieved. For both 
isotopes, the prescribed dose reduced when combined with external-beam radiation 
(Beyer, 2001). High dose rate brachytherapy (HDR-BT): 192Iridium is a radioactive 
isotope of Iridium, usually used as radiation source in this HDR-BT. Temporarily 
placed sources in prostate emit radiation to kill cancercells. This can be used as 
monotherapy or in combination with EBRT. TRUS guided target definition used to 
position the implants. A minimum of 100 Gy achieved within the prostate when used in 
combination with EBRT. This afterloading technique was developed in Kiel in the 80ies 
(Bertermann 1986) and then distributed that technique to Swedish hospital where it was 
modified and first introduced in 1988 (Borghede et al., 1997). 
2.6.3 High-intensity focused ultrasound 
This may be a treatment option in low-risk PC. However, evidence on efficacy is 
limited and there is a concern as PC is commonly multifocal. Therefore, this procedure 
should only be used with special arrangements for clinical governance or research 
(NICE guidelines, 2012). This offered as salvage therapy to patients with recurrent PC 
after EBRT, brachytherapy or proton therapy (Uchida et al., 2011).  
 
2.6.4 Cryotherapy 
This is an intervention that involves freezing of the prostate gland. It may be a treatment 
of choice for men with localized disease where radical prostatectomy is contraindicated, 
and is usually restricted to men with stage T1-2 N0M0 PC (Mouraviev & Polascik, 
2006). During cryotherapy, a cryoprobe inserted into the prostate under ultrasound 
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guidance and the prostate frozen to a temperature of −100° to −200° for approximately 
10 minutes (Mouraviev & Polascik, 2006).  Complications arising may be erectile 
dysfunction, urinary incontinence and urinary retention, rectal pain, and fistula. 
2.6.5 Endocrine treatment  
Use of androgen deprivation therapy in different settings depends on the intention for the 
individual patient. Orchiectomy: Testicular ablation or orchiectomy performed in acute 
situations, where spinal cord compression is an alarming sign (Damber & Peeker, 
2012). This is a very cost effective method and easy to perform, and an immediate 
castration level of testosterone will be achieved. 
  
Luteinizing hormone releasing hormone (LHRH) agonist/antagonist: LHRH 
agonists or antagonists are as effective as surgical castration (Damber & Peeker, 2012). 
It takes, however, two-four weeks to achieve castrate levels of testosterone with LHRH-
agonist but very quick effect achieves with LHRH-antagonist as surgical castration 
(Damber & Peeker, 2012). These drugs used sub-cutaneously every month, or every 
three to six months’ interval. They act on anterior pituitary gland to subsequent decrease 
the testosterone production by testes. Initial rise in testosterone noted in LHRH-agonist 
use, which usually prevented by adding anti-androgen.  
Antiandrogens: These drugs are acting by blocking androgen receptors, resulting in 
growth-inhibition of PC cells (Iversen et al., 2001; Berges & Tombal, 2008). They may 
be steriodal or non-steroidal. The testosterone levels in blood remain unchanged or 
increased. Neo-adjuvant anti-androgens, not advised in RP, but used as neo-adjuvant 
and concomittant treatment during curative radiotherapy, combined with LHRH-
agonist, and as adjuvant monotherapy in high risk PC. 
Estrogens: Estrogens used in advanced PC (Damber & Peeker, 2012). Risk for 
gynecomastia and cardiovascular morbidity increased with this treatment (Damber & 
Peeker, 2012). Parenteral adminstration have shown to diminish the cardiovascular 
morbidity (Henriksson et al., 1991). 
Total androgen blockade (TAB): The combination of antiandrogen and surgical or 
medical castration called total or maximum androgen blockade (TAB). This strategy 
used to minimize the testosterone to castration level (Prostate Cancer Collaborative 
Group, 2000; Klotz, 2008). This used in localized or metastatic settings. 
 
2.6.6 Deferred treatment: 
 
Active surveillance (AS) or watchful waiting may be the options used to different risk 
categories of PC depending on life expectancy and co-morbidities. AS may be an option 
suggested to men with longer life expectancy to maintain a follow-up schedule with 
PSA, DRE and core biopsy at regular intervals. AS is likely to produce a very modest 
decline in PC specific survival among men diagnosed with low-risk PC but could lead 
to significant benefits in terms of quality of life (Xia et al., 2012). The lack of clinical 
trials that directly compare various treatment modalities or identify the best management, 
especially for men with low-risk PC, makes the decision-making process difficult for both 
patients and physicians. Although general agreement exists on definition of candidates for 
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AS, men with low-volume and low-grade disease thought to be at low risk for rapid 
progression. Several key issues, such as optimal timing and appropriate triggers for active 
treatment remain to be established. The decision to initially pursue AS rather than active 
treatment after PC diagnosis is complex and involves factors, including estimation of life 
expectancy, consideration of quality of life, and assessment of ultimate oncologic 
outcome (Fung-Kee-Fung et al., 2013). Authors in a randomized trial comparing RP and 
watchful waiting showed reduction of disease specific mortality, overall mortality, risk 
of metastasis and local progression in RP compared to watchful waiting (SPCG-4) (Bill-
Axelson et al., 2005). In men with locally advanced PCa for whom local therapy may 
not be mandatory, watchful waiting is a treatment alternative rather than ADT, with 
equivalent oncologic efficacy (Mottet et al, 2015). 
 
 
2.6.7 Vaccine in prostate cancer  
 
Quite a number of clinical trials been conducted in PC with vaccination. Unique 
proteins expressed by PC cells are PSA, prostate-specific membrane antigen (PSMA) 
and prostatic acid phosphatase (PAP), which can be specifically, targeted making this 
disease suitable for vaccine-based approach (Kokhaei, 2006). Specific immune 
responses to vaccine, seen in trials, have a significantly longer median progression-free 
survival in responders (Small et al., 2000). In a placebo controlled randomized trial, an 
improvement in clinical outcome in patients with Gleason score maximum 7 found 
(Schellhammer et al., 2005). 
 
 
2.7 URINARY, SEXUAL AND BOWEL SYMPTOMS OF CURATIVE 
TREATMENTS 
 
Patients with locally advanced PC, randomized to RT + endocrine therapy vs. endocrine 
therapy alone in the SPCG-7 trial (Fransson et al., 2009). After 4 years, moderate to 
severe urinary bother were reported by 18% in the combination arm, vs. 12% in the 
endocrine arm. Corresponding figures for overall bowel problems were 11% vs. 7%, 
whereas 85% vs. 72% expressed having erectile dysfunction, respectively. Social 
function decreased in the combination arm. After 5 years, urinary, rectal, and sexual 
problems were slightly more frequent in the combination arm (Widmark et al., 2009). 
Dose escalation done with a 4-to 8 Gy-boost using the Beam-Cath technology (Beam 
Point AB, Umeå, Sweden) in 195 localized PC patients with 70-Gy conventional EBRT 
compared to another cohort of 168-patients treated with conventional way without 
increase in GI or GU late side effecs at 1 or 3 years’ post-therapy (Fransson et al., 
2002). 
In a 5-year follow-up study in PC patients treated with RP, external beam RT and 
brachytherapy without hormonal treatment, urinary irritative-obstructive adverse effects 
and some sexual dysfunction in EBRT and brachytherapy group observed (Pardo et al., 
2010). In addition, EBRT caused bowel bother. RP caused urinary incontinence and 
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sexual dysfunction, but improved pre-existing urinary irritative-obstructive symptoms. 
Relevant differences between treatment groups persisted for up to three years of follow-
up, although the difference in sexual adverse effects between brachytherapy and 
prostatectomy tended to decline over long-term follow-up (Pardo et al., 2010).  
Primary PC treatment often results in suboptimal urinary, bowel and/or sexual function. 
After treatment, the patients typically report high HRQoL scores. This discrepancy 
between disease-specific and generic results raises the question which meaning side 
effects actually have to patients. In a qualitative study with semi-structured interviews, 
the authors found two possible mechanisms, which could explain this discrepancy: 
insensitivity of generic HRQoL measures to these specific symptoms and adaptation to 
response shift (Korfage et a.l, 2006). Patients trivialized sexual (dys) function referring 
to old age and, did not view these dysfunctions as aspects of health. Many patients 
accepted the side effects as inevitable consequences of having being treated for PC, a 
condition they perceived as life threatening (Korfage IJ et al 2006). 
Volumetric modulated arc therapy/Intensity modulated RT are common techniques used 
to minimize side effects from surrounding normal tissues. In a Swedish study, mild GU-
symptoms were noted one year after RT compared to baseline; sexual symptoms 
deteriorated both during and after RT. Moreover, ADT-use was associated with worse 
sexual symptoms (Sveistrup et al., 2015). 
In a meta-analysis, authors found the predicted probability of maintaining erectile 
function after brachytherapy was 0.76, after brachytherapy plus EBRT 0.60, after EBRT 
0.55, after nerve-sparing RP 0.34, after standard RP 0.25 and after Cryotherapy 0.13 
(Robinson et al., 2002). 
Of the quality-of-life outcomes measured, erectile dysfunction is one of the most 
difficult outcomes to evaluate, as there is always a baseline variation.  Moreover, the 
psychological impact associated with cancer diagnosis and treatment morbidity makes it 
difficult to estimate erectile dysfuntion caused by the treatment (Garcia et al., 2015). 
The aggressiveness of the nerve preservation at the time of surgery, is a balance 
between oncological control and future functional outcomes (Tewari et al, 2008). RP is 
associated with urinary incontinence and sexual dysfunction (Steineck et al 2002). 
 
2.7.1  Radiotherapy-induced side effects  
   
The prostate gland is surrounded by urinary bladder, rectum and urethra. These organs 
are at risk for receiving radiation when the PC is irradiated. To plan a curative intent 
radiotherapy, it has to be considered that the prostate gland is very movable organ. 
Radiotherapy always has to be planned with margins in order not to miss the cancer. 
This in turn gives rise to radiation side effects, classified as acute or late.  
Acute side effects: Urethritis is the most common problem and variable. Most patients 
notice frequency, urgency and mild dysuria. Loose stool or diarrhoea may be another 
acute side effect, due to proctitis. In LDR, brachytherapy symptoms usually start after 4-
5 days and may persist in several months. Urinary retention develops in 10% of patients. 
In contrast, after HDR brachytherapy, urethritis develops within two weeks and rapidly 
resolves within 6 weeks (Whelan et al., 2014). Proctitis is more common after EBRT. 
Late side effects: Chronic cystitis/urethritis, urethral stricture, rectal bleeding, erectile 
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dysfunction may be debilitating late side effects of radiation for PC patients. 
Hypovascularity, decreased perfusion and fibrosis in irradiated areas seem to causing 
these symptoms. 
 
Radiobiological aspects: Radiation is a form of energy transport. Becquerel discovered 
the radioactivity in 1896 and extraction of radium by Marie Curie in 1898. The Linear-
Quadratic (LQ) model, which first proposed by Douglas and Fowler (Douglas & Fowler, 
1976), considers a model, which describes cell killing, both for tumor control and for 
normal tissue complications. Most common underlying biological rationale is that 
radiation produces a double strand DNA break (DSB) using a single radiation track. 
Individual DSB be repaired, but if more than one unrepaired DSB is present in the cell 
at the same time (arising from two separate radiation tracks), can produce a lethal 
lesion. A single radiation track can also give rise to a lethal lesion by itself (e.g. point 
mutation in vital gene, eliminating vital gene, induced apoptosis, etc.) (Brenner et al., 
1998). PC has a low growth fraction and has slow proliferation (Khoo et al., 1999; 
Haustermans et al., 1997). These characteristics are more typical of normal tissues 
exhibiting late reactions to irradiation (Duchesne et al., 1999). Late-reacting tissues 
have broad shoulder and steep falloff in cell survival curves, which have been 
characterized as having a low α/β ratio (α and β describe the linear and quadratic 
components of the cell survival curve). A majority of studies have estimated the α/β 
ratio for PC to be low, at approximately 1.5 Gy (Miralbell et al, 2012; Dasu et al., 
2012), whereas that for the surrounding normal tissues has been estimated to be >3 Gy. 
A low α/β ratio indicates greater sensitivity to higher radiation doses per fraction. The 
biologically effective dose (BED) formula depends on n fractions of d grays each 
modified by a factor 1+d/ α/β, the relative effect: 
                                               BED= nd*(1+d/ α/β)    
This allows for alterations of dose-per-fraction or dose rate without changing the 
effective dose.   
      
2.8 TREATMENT IN ADVANCED PROSTATE CANCER 
 
ADT has been the backbone of treatment for metastatic PC since the 1940s (Sweeney et 
al., 2015). ADT induces remission in 80 to 90% of men with advanced PC. Within two 
and a half years, however, an androgen-independent phenotype usually emerges 
(Hellerstedt & Pienta, 2002). Castration resistant PC (CRPC) arises when castration 
treatment fails (Pienta & Bradley, 2006). Three phase III trials in recent years compared 
ADT versus ADT plus Docetaxel: In CHAARTED trial docetaxel improved OS (HR 
0.61, 95% CI 0.47-0.80) (Sweeney et al., 2014). In GETUG-15 trial, similar 
progression-free survival (PFS) found but no survival difference (HR 1.01; 95% CI 
0.76-1.25) (Gravis et al., 2013). The STAMPEDE trial confirmed both PFS and OS 
benefit for adding docetaxel to ADT (James et al., 2016). Based on trials ADT 
recommended, as first-line treatment in metastatic hormone naïve disease, and docetaxel 
should be offered in men, fit enough for chemotherapy in this situation. Men treated 
with ADT have to be informed that regular exercise reduces fatigue and improves 
quality of life (Parker et al., 2015). Cabazitaxel, which is a semi-synthetic derivative of 
a natural taxoid plus prednisolone used to increase overall survival in second-line 
chemotherapy (de Bono et al., 2010). Immunotherapy with Sipuleucel-T, using 
activated autologous dendritic cells shown death reduction by 22% compared to placebo 
in men with asymptomatic or minimally symptomatic metastatic CRPC in pre-chemo 
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era (Kantoff et al., 2010), permitted in USA, but not in Europe. Corticosteroids 
minimize adrenal production of androgens and lead to favorable biochemical and 
clinical responses. Dexamethasone appears to be more active than prednisolone 
(Venkitaraman et al. 2015). Abiraterone acetate, CYP17 inhibitor, acts by inhibiting the 
synthesis of both estrogenic and androgenic steroids in CRPC (Reid et al., 2010; Danila 
et al., 2010; Ryan et al., 2010) shown to improve PFS significantly compared to 
placebo. Another androgen receptor antagonist, Enzalutamide, showed a 4.8-month 
advantage in median OS compared to placebo (Niraula et al., 2012). Abiraterone or 
Enzalutamide recommended for symptomatic men with chemotherapy-naïve metastatic 
CRPC (Parker et al., 2015). In the post-docetaxel setting, both drugs improved OS (de 
Bono et al., 2011; Scher et al., 2012). Palliation with EBRT against painful bone 
metastasis is frequently used. In situation with bone metastasis without visceral 
engagement, Alpharadin (Radium-223) is an alternative (Nilsson et al., 2013). 
Alpharadin is an alpha emitting nuclide that has shown improved OS and delay the time 
to first symptomatic skeletal event. Both bone metastases and fragility fractures due to 
bone loss result in considerable morbidity affecting QoL. Several bisphosphonates 
including alendronate, pamindronate and zoledronic acid, have shown to prevent bone 
mineral density loss in advanced PC patients (Michaelson et al., 2007). The biologic agent 
denosumab is more effective than zoledronic acid in preventing skeletal-related events in 
CRPC but not shown improvements in PFS or OS (Fizazi et al., 2011). 
 
2.9 HEALTH RELATED QUALITY OF LIFE AND PROSTATE CANCER 
2.9.1 Health related quality of life 
The term quality of life (QoL) can be found in different disciplines. Philosophers have 
since antiquity referred to QoL as “the good life”, while in psychology QoL refers to the 
mental state, in sociology to welfare, and in economics to the gross domestic product 
(Brulde, 2003; Cella, 1993a). In 1948, the World Health Organisation (WHO) introduced 
a concept of health by defining it as “a state of complete physical, mental and social well-
being, and not merely the absence of disease” (WHO, 1948). During the last decades, the 
interest has increased in patient-reported outcomes (PRO’s), defined as any report coming 
directly from the patient about a health condition and its treatment without the 
intervention of an observer (Cella, 1993a; Osoba, 2007). Health related quality of life 
(HRQoL) is one example of PRO’s.  
HRQoL is one of the important aspects of this thesis. Most definitions of HRQoL agree 
that the “concept is a multidimensional construct which includes patients’ perceptions of 
both negative and positive aspects of at least four dimensions of quality of life: physical, 
emotional, social functions as well as disease and treatment related symptoms” (Fayers, 
2007). HRQoL includes the subjective perception of symptoms and functions that only be 
understood from the patient´s point of view. Symptoms differ from signs. Signs are more 
objective such as body temperature, while symptoms are the patients’ subjective 
perception of disease and their expression of it, such as having pain (Rhodes, 1998). The 
concept of HRQoL emerged from the broader concept QoL, and is, by definition, more 
focused on aspects of life that influenced by or that can influence one´s health directly 
(Bergner, 1989). HRQoL in the present thesis, defined by the subscales, constituted with 
the responses to the items, in each scale.  
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2.9.2 Assessment of health related quality of life 
Increasing interest in the systematic assessment of HRQoL in cancer patients using 
standardized, self-administered measures has emerged over the past two decades (Cella et 
al., 2007). HRQoL is a patient-centered variable, measured using questionnaire also 
known as instruments. The questionnaires developed using principle of psychometric test 
theory and are evaluated rigorously before use to ensure that collected data are valid and 
reliable (Penson & Litwin, 2003). Instruments are best while using self-assessment and 
thus the patient is best suited to assess his/her HRQoL (Aronsson 1989; Cella 1994). The 
items in the questionnaires most often constructed in scales. Each scale measures a 
different aspect or domain of HRQoL. HRQoL- instruments should fulfill requirements 
such as reliability, validity, responsiveness, interpretability, practicality and applicability: 
Reliability: Refers to how reproducible an instrument or scale is. Test-retest reliability is a 
measure of response stability over time. Internal consistency reliability measures the 
similarity of an individual`s responses across several items, indicating the homogeneity of 
a scale. Multi-item measures considered more reliable as they are composed of several 
items allowing for more variation. 
Validity: Refers to how perfect a scale or instrument measures the attribute it intended to 
measure. Content validity refers to qualitative assessment of a proposed scale whereas 
criterion validity refers to a quantitative approach. Construct validity refers to measure 
how well the scale or survey instrument performs in a multitude of settings and 
populations over a number of years. 
Responsiveness: Refers to how sensitive the scales are to changes over time or in stages 
of illness (Fayers et al., 2005). 
Interpretability: Refers to the degree to which meaning to the scores obtained by a 
measure, for instance presence of meaningful reference groups. In longitudinal studies, 
patients may serve as their own controls. Clinically relevant mean score differences have 
been suggested for some of the cancer specific HRQoL questionnaires (King 1996; Osoba 
et al., 1998). 
Practicality: Refers to ensuring data quality by minimizing the bias. A questionnaire 
should be short and easily completed, and the procedures should be standardized and 
clearly described in the study protocol. 
 Applicability: Refers to the usefulness in a given population with respect to cultural and 
linguistic characteristics. This adaptation process follows a strict order and questionnaires 
used been tested in the appropriate cultural setting. 
2.9.3 HRQoL instruments 
A number of instruments been developed for the assessment of HRQoL. Irrespective of 
illness or the condition of the patient, instruments like Short Form-36 (SF-36) (Ware et 
al., 1992) and the Nottingham Health Profile (NHP) (Hunt, 1981) measure HRQoL. 
Cancer-specific instruments, developed in international collaboration, include the 
European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core-30 (EORTC QLQ-C30) (Aronsson et al., 1993), which been used in 
the present thesis. Another questionnaire originally validated for cancer patients is a 
general quality of life instrument intended for use with variety of chronic illnesses called 
Functional Assessment of Cancer Therapy-General (FACT-G) (Cella et al., 1993). 
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For evaluation of disease-specific HRQoL in PC, there are several questionnaires, such as 
the Expanded Prostate Cancer Index (EPIC) (Wei et al, 2002), Patient-Oriented Prostate 
Utility Scale (PORPUS) (Krahn et al, 2000), Prostate Cancer Quality of Life Instrument 
(PC-QoL) (Schmidt et al., 2014), The University of California Los Angeles Prostate 
Cancer Index (UCLA-PCI) (Litwin et al., 1999) and the prostate FACT (FACT-P) (Esper 
et al., 1997). The EORTC Quality of Life Questionnaire Prostate-25 (EORTC QLQ-
PR25), developed by the EORTC Quality of Life Group (Borghede et al., 1996). It is a PC 
specific questionnaire, validated in an international study (Van Andel et al., 2008), and 
used in the present thesis. The Prostate Cancer Symptom Scale (PCSS) (Fransson et al., 
2001) and the questionnaire used in the SPCG-4 study developed in Sweden for the 
assessment of HRQoL in PC patients (Steineck et al., 2002). Questionnaires used in this 
thesis presented in Table 8. 
2.9.4 Health related quality of life in prostate cancer 
2.9.5 HRQoL and PC surgery 
Surgical intervention is associated with erectile dysfunction (ED) and urinary 
incontinence (Alemozaffar et al., 2011; Resnik et al, 2013). Nerve sparing RP in one 
study did not show any difference in sexual function compared to men who underwent 
non-nerve sparing technique (Talcott et al., 1997). In another study, however, 
significantly better sexual function reported in men who underwent nerve-sparing 
surgery (Litwin et al, 1999). Similar conclusions drawn from in a study in which nerve-
sparing procedures were associated with better recovery of sexual QoL than procedures 
that were not nerve-sparing (Sanda et al, 2008). Incontinence and impotency rates of 
66% and 88%, respectively, were reported in another study of 1 069 patients during 
post-prostatectomy period of six months (Kao et al., 2000). A complete impotency rate 
of 75% and incontinence rate of 35% at 12 months after RP observed (Talcott et al, 
2001). In a longitudinal study, >90% of the patients recovered to baseline in all domains 
at 12 months. By this time 56% recovered their urinary function. Mean recovery time 
for sexual function from baseline was eleven months (Litwin et al., 2001). In one study, 
8 % of PC patients remained continent after >18 months’ post-surgery, whereas 60 % 
reported being impotent (Stanford et al, 2000). A multi-institutional longitudinal study 
revealed delayed recovery of urinary and sexual function in patients who underwent 
laparoscopic-RP, which appeared to affect their general HRQoL (Namiki et al., 2005). 
Taking age-related changes into account, general HRQoL-scores seemed to remain 
stable after RP, where the authors found no significant differences in any of the eight 
domains of the physical composite score at eight years’ follow-up. About 15% reported 
urinary leakage at the one-year assessment, which remained at five years’ follow-up. 
About 85% considered their ability to have an erection as “poor” or “very poor” beyond 
five years (Namiki et al., 2014). 
 In a large Swedish prospective, randomized controlled trial, HRQoL were compared 
between men receiving RP and men on watchful waiting (Bill-Axelsson et al., 2011). 
Five year outcomes revealed more erectile dysfunction (80% vs. 45%) and urinary 
leakage (49% vs. 21%), but less urinary obstruction (28% vs. 44%) in men who had 
undergone prostatectomy (Steineck et al., 2002). Bowel function, anxiety, depression, 
well-being, and overall HRQoL were similar in the two groups after five years, but at 
six to eight years, anxiety and depression deteriorated significantly for those who chose 
watchful waiting (Johansson et al., 2009).  
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In summary, RP influences HRQoL by decreasing functions in sexuality and urination. 
Controversy remains about method of choice to minimize sexual problems, but the 
nerve-sparing technique is to be preferred in order to retain sexual function. Urinary 
incontinence after RP is a common problem, which gradually diminishes in longer 
follow-ups. Bowel function appears not a problem after RP.                
HRQoL and PC radiation therapy (RT) 
RT regimens are formulated based on PC risk-level, where radiation with or without 
ADT can be chosen. Recovery of sexual function was worse among patients who 
received EBRT and androgen-suppression therapy combined with RT than in those who 
received RT alone in a randomized study (Sanda et al., 2008). Urinary symptoms 
improved over baseline after 24 months. Patients in the brachytherapy group reported 
significant detriments in urinary irritation or obstruction and incontinence, compared to 
baseline. Erectile dysfunction been reported to have a maximum drop at 3 months’ post-
RT, with a recovery at one year, been found to remain stable at two and three years’ 
follow-up (Budäus et al., 2012; Incrocci & Jensen, 2013). In a Swedish study, generally 
high levels of HRQoL were noted in patients treated with combined EBRT + HDR BT 
+ ADT, in spite of persistent urinary urgency, increased stool frequency and erectile 
problems five years’ post-treatment (Wahlgren et al., 2005). In a randomized study with  
conventional versus hypofractionated regimens in intermediate-risk localized PC, 
authors found low incidence of patient-reported bowel symptoms and were similar in 
compariaon to randomized groups (Wilkins et al., 2015). 
In short, RT influences HRQoL by increasing urinary irritative/obstructive symptoms in 
the acute phase, mainly after brachytherapy, whereas bowel function deteriorates after 
EBRT. RT negatively influences both sexual- and urinary functions, and sexual 
functions more influenced by the addition av ADT. Hypofractionated regimens might be 
used in intermediate-risk PC without compromising HRQoL.  
HRQoL and comparison between radiation therapy and radical prostatectomy 
 
Treatment modalities for localized PC have shown treatment-related side effects such as 
incontinence, bowel disturbances, and impact on sexual activity (Wei et al., 2002; Frank 
et al., 2007). In a cross sectional study, comparing HRQoL between RP and a combined 
EBRT & HDR-brachytherapy, compared with normative data; high levels of overall 
QoL found in both groups, comparable with normative data (Hjälm-Eriksson et al, 
2015). Statistically significant differences in bowel and urinary problems noted favoring 
RP-group, however clinical significance rated there small. No differences in sexual 
functions noted between the groups. Older men in a population-based study, observed to 
have urinary incontinence (15%) or decreased bowel functions (6%) (Litwin, 1999). 
HRQoL-studies in 3D-CRT-treated PC patients revealed urinary incontinence in 13-
23% (Hanlon et al., 2001; Shrader-Bogen et al., 1997; Litwin et al., 1995), whereas for a 
combined EBRT-BT, 12-24% indicated daily urine-leakage (Joly et al., 1998; Talcott et 
al., 2001). In RP-treated patients, urinary leakage reported by 40-46% of the patients 
(Litwin et al., 1995; Shrader-Bogen et al., 1997; Yarbro et al., 1998). Comparing 
HRQoL-variables between RP or LDR-brachytherapy treated men, significantly lower 
scores in physical, social and role functioning in the RP-group noted during the first 
three months, but these returned to baseline at six months. In the LDR-group, no 
significant decrease in HRQoL-scores noted during the first 12 months’ post-treatment 
(Namiki et al., 2006). 
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In summary, overall HRQoL in patients treated by RP or RT (combined technique with 
EBRT + Brachytherapy) is comparable with that of normative data. Level of urinary 
incontinence in men lies around 25% treated by RT, irrespective of techniques, 
compared to >40% in RP-treated men. Erectile dysfunction seems problematic in all 
modalities. 
 
HRQoL and androgen deprivation therapy 
 
An overview of HRQoL studies related to ADT treatments shown in table 2. 
There are relatively few papers reporting on the effects of ADT on HRQoL. An 18-
years follow-up study reported better HRQoL in RP than in EBRT or ADT alone group 
(Drummond et al., 2015). Poorer urinary-and sexual function in PC patients treated by 
RP, RT, or ADT compare to surveillance found in a cohort study of 699 patients. 
HRQoL scores improved in RP group compared to ADT and surveillance after 12 
months (Lubeck et al., 2001). Another cohort study reported 80% impotency in ADT 
users after one year compared to 30% impotency in patients without ADT (Potosky et 
al., 2002). In a prospective longitudinal study gradual decreased physical functioning, 
role functioning and vitality were found in ADT users, compared to those with PC-
controls and healthy-controls after one year (Alibhai et al., 2010). 
In summary, ADT decreases sexual quality of life. In long-term follow-up, RP patients 
improve and appear to have better sexual functioning compared to patients treated with 
EBRT or ADT alone.  
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Table 2: Overview of HRQoL studies and ADT 
 
Author Journal/
Year 
Study design 
and purpose 
Number 
of         
patients 
RP/RT and ADT Instrument Assessment 
point after 
therapy 
Results Conclusions 
Basaria et al. Clin 
Endocrin 
2002 
Cross 
sectional  
n=58 n=20 (ADT 12 
months) 
n=18 (nonmetastatic 
RP/RT)  
n=20 (age-matched 
controls) 
 
Watts sexual 
function 
questionnaire 
and other 
measures to 
examine 
bone and fat 
mass 
Baseline and 12 
months 
BMD significantly lower in ADT 
than in comparison groups; lower 
scores in overall sexual function-and 
QoL scores noted in ADT; ADT 
patients were more limited in 
physical-and role functioning 
Osteoporosis, unfavorable 
body composition, sexual 
dysfunction and reduced 
HRQoL were found in ADT 
after 12 months. More 
studies were warranted 
Drummond et al. J Cancer 
Surviv 
2015 
Cross- 
sectional 
HRQoL up 
to 18 years 
n=6559 EBRT 34%,             
RP 28%,              
EBRT + ADT 18%,                
ADT 9%,  
Observation 5%,     
BT 4% 
 
EORTC C-
30, EORTC-
PR25 
Once at three 
time points after 
diagnosis:       
<5 yrs; 
 5-10 yrs;     
>10 yrs                                              
Response rate 54%, HRQoL was 
better in RP than EBRT or ADT 
alone; but were similar compared to 
other groups 
Long-term HRQoL varied in 
survivors depending on the 
treatment given 
Lubeck  et al. Urol 2001 Cohort study n=699 n=106 (surveillance) 
n=167 (ADT) n=351 
(RP) n=75(RT) 
UCLA-PCI 
SF-36 
Baseline and 
every 3 months 
up to 9 months 
ADT had poorer urinary and sexual 
function, higher urinary-and sexual 
bother, as in RP-and RT groups 
compared to surveillance. In ADT-
and surveillance groups, HRQoL 
scores remained low at 12 months, 
but RP group showed improvement.                                               
Longer follow-up needed 
after ADT start to know the 
impact on HRQoL  
Potosky et al. J Natl 
Cancer 
Inst 2002 
Population 
based cohort 
study 
n=661 n=245 (ADT) 
n=416 (no therapy) 
SF-36 Base line and 1 
year after 
therapy 
88 patients potent before ADT, 80% 
became impotent at 1 year and had 
more physical discomfort, statistically 
significant decline in vitality, but 
more satisfied with treatment decision 
56% compared to controls (45%).               
223 controls (no therapy) were 
potent, but 30% became impotent 
after 1 year. 
Physical wellbeing and 
sexual function should be 
considered in the first year 
following treatment with 
ADT 
Alibhai et al. JCO 2010 Prospective 
longitudinal 
study 
n=259 n=87 (ADT) 
n=86 (PC controls) 
n=86 (Healthy 
controls) 
SF-36 Baseline, 3, 6, 
12 months 
 Six minutes walk test was stable in 
ADT-group, but improved in both 
controls. Physical function decreased 
in ADT users especially at 12 month, 
even role function and vitality 
decreased gradually compared to 
controls 
Components of QoL are 
affected within 3 months of 
starting ADT. Up-front 
exercise interventions are 
warranted. 
N=number, BMD= Bone mineral density, BT=Brachytherapy, RP=Radical prostatectomy, RT=Radiotherapy, ADT=Androgen 
deprivation therapy, HRQoL=Health related quality of life, QoL=Quality of life, EBRT=External beam radiation therapy, 
EORTC=European organization for research and treatment of cancer, C30=Core 30, PR25=Prostate cancer module 25, UCLA-PCI= 
University of California and Los Angeles Prostate Cancer Index. SF-36= Short Form 36. 
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HRQoL and active surveillance (AS)  
 
In a Finnish study, no short-term quality-of-life disturbances noted in patients who had 
adopted AS. None of the patients changed treatment due to anxiety. Surprisinglyly, PC 
patients on AS, had significantly better mental-and physical HRQoL compared to a 
general age-stratified Finnish male population (Vasarainen et al., 2012).  
 
 
2.9.6 Information and Health Related Quality of Life 
Shared treatment decision making is a process of interaction between a physician and a 
patient in which information exchanged about treatment options, personal preferences 
of the patient, the most relevant choices are deliberated and a decision jointly made 
about the treatment to be implemented (Charles et al., 1999). Shared decision-making 
considered an essential component of delivering patient-centered care (Carter et al., 
2013). In light of evidence that survival and clinical outcomes may be similar across 
treatments for many conditions, HRQoL considerations may be the critical factor in 
medical decision-making (Bergman & Litwin, 2012). Providing adequate information 
to cancer patients facilitate their adjustment to the cancer experience by increasing 
perceptions of control, reducing feelings of threat and anxiety, and in improving 
HRQoL (Lerman et al, 1993; Meredith et al., 1996; Thomas et al., 1999). Satisfaction 
with information has shown to contribute to physical and social well-being (Davies et 
al., 2008). Adequate information enhances patients´participation in their treatment 
decision-making consultations, follow-ups, and at the same time coping with side 
effects (Bergenmar et al., 2014). Unmet information needs about the disease and its 
progression linked to negative psychological outcomes such as anxiety and depression 
(Mesters et al., 2001). Information provision is a key component of supportive care 
throughout the cancer trajectory and the prevalence of unmet needs do not seem to 
diminish in patients at follow-up (Harrison et al., 2009). 
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3 AIMS 
 
Paper 1: to study how PC patients perceive information given at their visits before, during 
and after completion of curative intented radiation therapy, adopted either primarily or as 
salvage-radiotherapy after post-surgical PSA relapse. Another aim was to examine the 
relationship between health related quality of life and information needs. 
Paper 2: to prospectively study differences in health related quality of life and side-effects 
between patients randomized to radical prostatectomy or combined external radiotherapy and 
high dose rate brachytherapy. 
Paper 3: to prospectively study differences in quality of life in PC patients randomized to 
anti-androgen versus total androgen blockade in curative intended radiotherapy. 
Paper 4: to study differences in prostate volume in curative intended PC patients randomized 
to anti-androgen versus total androgen blockade in curative intended radiotherapy. 
  
  26 
4 PATIENTS AND METHODS 
4.1 PATIENTS 
 
Paper 1: Questionnaires sent to 660 consecutive patients with PC, who had undergone or 
planned to undergo radiotherapy (RT) with curative intent between December 2006 and 
March 2010 at the Department of Oncology, Karolinska University Hospital, Sweden. 
Eligible patients were identified in the computerized system for patients’ medical files. 
Patients with metastatic disease or PSA relapse after curative intended RT during the study 
period were excluded (n=4), leaving 656 patients in the final sample.  
Paper 2: A total of 89 men with localized/locally advanced PC, clinical stage T1b–T3a, N0, 
M0 (UICC, TNM, 1992), and a PSA value ≤ 50 ng/ml were randomized between RP versus 
combined external radiotherapy (EBRT) and high-dose-rate (HDR) brachytherapy in 1996–
2001 in Gothenburg, Uppsala, Linköping, Eskilstuna, and Stockholm. Prior to inclusion, the 
patients given full oral and written information about the study and the respective treatment 
modality, and provided written informed consent. All included patients underwent total 
androgen blockade during six months.  
Paper 3 and 4: 110 patients with localized/locally advanced PC, referred to the Oncology 
Department at Radiumhemmet, Karolinska University Hospital, Sweden for curative intended 
radiotherapy, were included between 2005 and 2011 and randomized between anti-androgen 
(AA) or total androgen blockade (TAB). Eligible patients screened at the Clinical Trials Unit 
at the Department of Oncology for inclusion in the study. Randomization was done after 
informed consent, with a ratio 1:1.  
 
4.2 PROCEDURE 
 
Paper 1: In April 2010, questionnaires, together with an information letter about the study, 
and a prepaid return envelope sent to the patients from the Unit for Outcome and Quality 
Assessment at the Oncology Department, Karolinska University Hospital. One reminder 
sent, together with a new questionnaire and return envelope after three weeks to those who 
did not return questionnaires. 
 
Paper 2: HRQoL was assessed at three occasions: before randomization, and 12 and 24 
months after randomization. The physician or study nurse handed the first questionnaire to 
each patient, which completed before randomization. At the subsequent assessment points, 
the questionnaires and pre-paid return envelopes sent to the patients’ home address from the 
Department of Oncology, Sahlgrenska University Hospital, Gothenburg. 
Paper 3: After informed consent, the patient responded to the questionnaires before 
randomization, the first point of assessment.  HRQoL then assessed at additional five points: 
before start of RT (3 months), and subsequently 9, 12, 15 and 18 months after randomization. 
Questionnaires were sent with a return envelope at these assessments. The patients could 
choose to return questionnaires by post or during visits at the oncology clinic.  
Paper 4: The patients’ PV’s were assessed before start of endocrine neo-adjuvant treatment 
(Volume 1) and before start of radiation therapy (RT) (Volume 2). The PV assessment was 
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performed by transrectal ultrasound before giving definitive recommendation of treatment 
with curative intention. The second PV assessment was conducted after three to six months of 
neo-adjuvant hormonal therapy before start of combined RT.  Two oncologists measured the 
volumes at archive pictures taken during ultrasound to confirm the volumes. 
 
4.3 INSTRUMENTS 
The European Organization for Research and Treatment of Cancer Quality of Life Core 
Questionnaire (EORTC QLQ-C30) was used to assess HRQoL in Paper 1, 2 and 3 (Aaronson 
et al., 1993).  In Paper 2, an earlier version, consisting of 33 items was used. The EORTC 
QLQ-C30 version 3 including 30-items was used in Papers 1 and 3. The questionnaire 
consists of functional and symptoms scales together with individual items. The five 
functional subscales are physical, role, social, emotional and cognitive. Fatigue, 
nausea/vomiting and pain are three symptoms scales. Six individual items are also included: 
dyspnoea, appetite loss, insomnia, diarrhoea, constipation, and financial difficulties. All items 
are scored in four point-scales (1=not at all, 4=very much). Moreover, there are two items 
addressing global health/QoL, scored on a seven-point scale (1= Very poor; 7= Excellent). 
The Swedish version of the questionnaire has been validated (Sigurdardottir et al., 1996). 
The European Organization for Research and Treatment of Cancer Quality of Life Prostate 
Cancer Questionnaire (EORTC QLQ PR25) used to assess PC specific HRQoL in Papers 2 
and 3. The initial version of this questionnaire, consisting of 20 items, used in Study 2 
(Borghede et al., 1996). This was the first version of the questionnaire, developed in 
Gothenburg, Sweden, to gather information on side effects experienced by PC patients 
regarding bowel, urinary tract, and sexual functions. EORTC-PR25 includes four subscales. 
The four subscales aim at assessing urinary symptoms (9 items), bowel symptoms (4 items), 
treatment-related symptoms (6 items) and sexual functioning (6 items). The response format 
is similar to most items in the core questionnaire (1= not at all, 4= very much).  EORTC QLQ 
PR25 has been validated in an international study (van Andel et al., 2008). 
 
The European Organization for Research and Treatment of Cancer Quality of Life 
Information Questionnaire (EORTC QLQ INFO 25) was used in Paper 1 to gather 
information about patients’ perception of information given and their satisfaction with that 
(Arraras et al., 2010). Total 25 items, divided into 4 multi-item categories including disease 
(4 items), medical tests (3 items), treatment (6 items), other services (4 items) and 8 single-
item scales (information about different places of care, things you can do to help yourself 
get well, written information, information on CD and tape/video, satisfaction with 
information received, wish for more or less information, and if the overall information had 
been helpful). Response format for 21-items is a 4-point scale from 1 (“Not at all”) to 4 
(“Very much”) and for 4 items “yes” or “no.” The questionnaire has been validated in an 
international study (Arraras et al., 2011).  
 
5 STATISTICAL ANALYSES 
 
Paper 1: Item scores for EORTC QLQ-C30 and EORTC QLQ INFO25 were transformed 
into 0-100 scales. Higher scores in functional subscales and overall quality of life indicate 
higher function and QoL, but denote more problems in symptom scales. Five selected items 
from QLQ C30 (emotinal functioning, cognitive functioning, global QoL, fatigue & pain) 
were selected for this study. A linear regression model was used to study the association 
  28 
between clinical and demographic variables with HRQoL and EORTC-INFO25 scales, both 
in the univariate and multivariate analyses.  
 
Paper 2: Item scores for EORTC QLQ-C33 and EORTC QLQ-PR25 were transformed into 
0-100 scales. A 20 symptom-questionnaire was used (the earlier version of PR25). ANOVA 
repeated measurements were performed to evaluate differences between randomization 
groups, time and group-by-time interactions. Survival analysis done by Kaplan-Meier 
technique. The Swedish Death Registry was used to identify the number of deaths at follow-
up.  
 
Paper 3: Item scores for EORTC QLQ C30 and EORTC QLQ-PR25 were transformed into 
0-100 scales. Survival was estimated using the Kaplan-Meier technique. Linear regression 
model was used to analyse between-group-differences and variations over time.  
 
Paper 4: Linear regression model was used to study groups at baseline and at follow-up. At 
follow-up visits, differences were studied both with univariate and multivariate analyses. P-
values from these models refer to Wald-test. Paired t-test was used to study changes over 
time in each group between baseline and follow-up. Unpaired t-tests were performed to 
compare changes in PV and in planning target volumes between the randomization-groups. 
 
 
 
Table 3: Overview of statistical methods used in studies I-IV 
 
 STUDY I STUDY II STUDY III STUDY IV 
Paired t-test 
 
          x 
ANOVA 
repeated 
measurements 
        x   
Kaplan-Meier 
analysis 
        x         x  
Log rank test 
 
          x  
Linear 
regression 
model 
        x        x         x        x 
Wald test 
 
        x          x        x 
Fishers-exact 
test 
        x   
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6 RESULTS 
 
Paper 1: A total of 92% (n=603) responded to the questionnaires in this cross-sectional 
study. For the item about satisfaction with information, 159 (27%) patients indicated “very 
much,” 248 (42%) “Quite a bit,” 143 (25%) “a little,” and 35 (6%) “not at all”. Younger 
patients reported having received more information about “other services” than older 
patients did (p<0.001). Patients who’s first visit to the oncology clinic had occurred ≥ 1 
year before completion of the questionnaires, reported having received more information 
about disease (p<0.001) and medical tests (p=0.002) than those who visited during the last 
year. We found statistically significant differences for “satisfaction with information” 
(p=0.002), and the “amount of information received” (p<0.001 for all differences), favoring 
the RT alone group in comparison to surgery + salvage RT. No interactions between 
treatments and time found for any of the subscales. There were statistically significant 
associations found between the EORTC QLQ-C30 variables analysed in this study, and 
“satisfaction with information” (P<0.001). Higher satisfaction was associated with better 
functioning and lower levels of symptoms.  
Paper 2: A total of 89 patients were randomized between RP and RT in this curative 
intended multi-center study. A total of 66% completed questionnaires at all three 
assessment points. No statistically significant differences in HRQoL or treatment related 
symptoms and problems were found between the groups. A statistically significant 
improvement in emotional functioning over time was noted in both groups (p<0.001), 
although social functioning decreased (p<0.01) with time and financial difficulties 
increased (p=0.001). There were no statistically significant group-by-time interactions 
found. The study was underpowered, as it was closed before the intended number of 
patients could be recruited. Therefore, it was not possible to draw any conclusion about 
differences in efficacy between the treatments.  
Paper 3: A total of 110 men were included in this randomized trial. Statistically significant 
differences between the groups at the 3-months assessment, favoring the AA group were 
found for overall quality of life (p=0.006), fatigue (p=0.023), sexual interest (p<.001), and 
urinary problems (p=.036). The difference in sexual interest was clinically “large”, and for 
sexual functioning “moderate”. At the 18- months assessment, statistically significant 
differences, favoring the AA group, were found for cognitive functioning (p=0.040) and 
sexual interest (p=0.011), the latter denoted as a “moderate” clinical difference. Statistically 
significant interactions over time were found for overall quality of life, cognitive functioning, 
fatigue and sexual interest, indicating that HRQoL scores developed differently between the 
randomization groups. At the median follow-up of 6.9 years, twelve PSA progressions 
(AA=8, TAB=4) and eight deaths (AA=5, TAB=3) were observed. Among these, one in each 
group denoted as PC-specific death. No statistically significant differences in OS or PSA-
progression-free survival were found between the groups.  
Paper 4: A total of 110 patients were included in the neo-adjuvant study, but 22 patients 
were not included in the final analysis (no PV information at baseline, n=11, 10%; treated 
with EBRT alone, n=11, 10%), leaving 88 patients (80%) to be analyzed in the final sample; 
45 patients (51%) in the AA group and 43 patients (49%) in the TAB group.  
TAB was more effective in PV reduction as compared to AA (p<0.001). Mean PV reduction 
was 16 % in the AA group compared to 29% in the TAB group. In the AA group, PV was 
reduced by ≥20% in 23 patients (51%). Corresponding figure for the TAB group was 34 
patients (79%). PV was increased by ≥10% in 4 patients (8%) in the AA group and in 1 
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patient (2%) in the TAB group. The time between the assessments was similar in both 
groups, median 13 weeks. There was no statistically significant difference in duration of neo-
adjuvant treatment or in clinical and demographic variables between the two groups. 
 
7 DISCUSSION 
 
Paper 1: The results of the study indicates substantial options for improvement regarding 
the information provided to PC patients undergoing RT. Younger, as compared to older 
patients reported having received more information about “other services”, which is in 
concordance with previous studies, conducted in heterogenous groups of cancer patients 
(Arraras et al., 2011; Pinquart et al., 2004). Younger patients might be more prone to seek 
information themselves, e.g. through Internet. A positive association between HRQoL and 
satisfaction with information found, higher levels of HRQoL among satisfied patients. 
There are several explanations for this finding. One possible explanation is that, those who 
have better HRQoL provided with more adequate information, have been less anxious and 
able to comprehend the information. Another explanation is that adequate information 
affects patients’ HRQoL in a positive way. Our result supported by a review of associations 
between information provision and HRQoL (Husson et al., 2011). Patients who had 
curative RT alone indicated higher levels of information than those who had RP + salvage 
RT. This finding might be explained by the fact that those who had RT alone mostly treated 
with neo-adjuvant ADT, implying multiple contacts with nurses, and thus, a possibility to 
get more information and to ask questions. Another possible explanation is that those who 
had RT after surgery due to PSA-relapse were disappointed and more worried. Our results 
indicate that it is of utmost importance to thoroughly inform patients who are about to 
receive RT in a salvage setting, and not rely on that they have been previously informed 
about. 
 
Patients who responded to the questionnaires ≥ 1 year after their first visits at the oncology 
clinic reported having received more information about the disease and medical tests, which 
expected as they had more time to get information. There was no difference, however, in 
satisfaction with information between these two groups.  
 
Paper 2: Our study represents the first report of a prospective randomized controlled trial 
comparing RP versus combination RT with EBRT & HDR-brachytherapy. This multicenter 
Swedish study intended to include 360 patients, but due to initiation of concurrent studies 
(SPCG-4 & SPCG-7), it was impossible to include patients as planned. Moreover, another 
study showed no differences in PFS in RP by adding neo-adjuvant endocrine therapy (Aus 
et al., 1998). The study closed in 2002 after including 89 patients. No statistically 
significant differences found for HRQoL and complications between the randomization 
groups, possibly due to the low sample size. The levels found were comparable with those 
found in a previous Swedish study, and similar to normative data from Swedish men 
(Wahlgren et al., 2004). Sexual problems were common in both groups at two years’ post- 
treatment, probably as side effects of given treatments and due to aging. No conclusions 
drawn regarding survival or efficacy of treatment modalities, as the study was 
underpowered. 
 
Paper 3: To our knowledge, this is the first prostpective trial randomizing anti-androgen 
versus total androgen blockade in curative intent RT in PC patients. At the three months’ 
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assessment, statistically significant higher levels of overall quality of life and sexual interest, 
together with lower levels of fatigue and urinary problems reported in AA-group compared to 
TAB-group. Patients with higher sexual interest also showed significantly better sexual 
functioning. Our findings are similar to those reported by Iversen et al in locally advanced PC 
patients after 6.3 years of follow-up (Iversen et al, 2000).  Sexual interest and physical 
functioning were better in the AA-group compared to castration-group. The mortality rate in 
that study (56%) was higher than in our study, which explained by patient categories (T3-T4), 
compared to our study where mostly an intermediate-riskgroup was included. In addition, the 
follow-up was longer, compared to our study. One patient in each group got PSA relapse 
around 11 months after randomization in our study. The patient in the AA arm (treated with 
EBRT only) missed 7 weeks of anti-androgen treatment at neo-adjuvant setting due to 
misunderstanding whereas the patient in TAB arm (treated with combination of HDR-BT and 
EBRT) found to have a more advanced tumor stage than anticipated at baseline. Deaths due 
to other causes were four (7%) in AA group compared to two (4%) in TAB group. This study 
is the first study, randomizing AA versus TAB in an intermediate-risk group of prostate 
cancer patients.  
Paper 4: Prostate volume (PV) plays an important role in radiation planning with curative 
intention in PC patients, since large target volumes may affect organs at-risk causing 
subsequent radiation-related side effects and thus influence HRQoL negatively. Greatest falls 
in the radiation dose needed to kill 50% of cell population occur when maximum reduction in 
tumour volume occurs before EBRT, showed in an in-vivo study (Zietman et al., 1997). Neo-
adjuvant ADT minimizes PV (Zelefsky et al, 1994; Henderson et al., 2003). In the present, 
prospective study, TAB significantly decreased PV more than AA treatment. Our results are 
comparable with other studies in this field (Lee 2002; Merrick et al., 2006; Petit et al., 2008). 
Suprisingly, ≥10% PV increase was found in four AA-patients and in one TAB-patient. This 
might be explained by inter-physician variablitity in PV assessment. 
Overall quality of life, sexual interest, fatigue and urinary problems significantly differed in 
the present study at 3-months assessment, favouring men in AA-group compared to those in 
TAB-group (Paper 3). In addition, at the 18-months assessment, men in AA-group reported 
higher levels of sexual interest and cognitive functioning, and there were no differences in 
urinary or bowel symptoms. This was surprising as better HRQoL in the TAB-group 
expected as these patients received RT using smaller target volumes, and correspondingly 
lesser surrounding normal tissues. We assume that, as combined EBRT BT was the treatment 
modality in both groups, some positive effects in symptoms outweighed by brachytherapy 
side effects.  
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8 ETHICAL CONSIDERATIONS 
 
Paper 1: The patients in this study generated from medical files at Radiumhemmet, 
Karolinska University Hospital where patients visited at least once, all got curative intent RT 
against localized prostate cancer. Patients may find the questionnaires sent home as integrity 
hampering as they reminded of their cancer diagnosis. We have, however, previous 
experience of this method and most patients do not seem to have any problems with the 
procedure. Patients may find this is an opportunity to consider their need for information, and 
might take some actions to gain more information. It may be tiredsome to fill-in the 
questionnaires with a total of 55 questions, but considering the high response rate, we do not 
believe that the length of the questionnaire was a problem for the patients. It is shown in 
studies that patients feel comfortable with health care but not always satisfied with 
information they have received, and thus, appreciate that this topic is being studied.  
Paper 2: The patients in this study were included in a randomized study between 1996 and 
2001 in five centre. Patients randomized to receive treatments with curative intention, RP or 
RT of combination technique. Patients who randomized to prostatectomy went through a 
laparoscopic operation first if they had high-risk of metastatic disease according to pre-
defined criteria, in order to explore if there was any spread to the regional lymph nodes. This 
procedure could result in proceeding to RP or not. Thus, high-risk patients had to go through 
an operation with some anxiety. On the other hand, they were prepared thoroughly. In 
addition, TAB was given to all patients including those randomized to RP, although this was 
not a routine procedure in clinical practice. Patients castrated temporarily with this treatment 
which might have caused negative impact on their HRQoL. On the other hand, patients 
included in clinical studies might have easier access to medical care compared to those who 
are not. The patients were requested to complete HRQoL questionnaires, which might have 
caused anxiety or worries. We got, however, no indications about problems caused by the 
questionnaire-part of the study and our previous experiences with collecting HRQoL 
questionnaires in connection with cancer clinical trials are positive. Most patients appreciate, 
that these important aspects are studied in addition to the clinical problems. 
Paper 3 & 4:  The experimental arm, AA, was considered safe according to previous studies. 
In the original protocol, a substantially larger sample size was calculated in order to make an 
analysis of OS and TTP. In second amendment, anti-estrogen was allowed to use whenever 
needed if side effects of antiandrogen are bothersome. By this time thirteen patients were 
included who did not have that availability of anti-estrogen. But as we know that only twelve 
patients used anti-estrogen in total, eleven in antiandrogen group and one in TAB group, it 
was not a big ethical problem in this age group. Due to low accrual rate, a new calculation of 
sample size was performed based on HRQoL. It may be considered as an ethical problem that 
OS and TTP analyses cannot be performed in this group of low risk PC. Our follow-up 
figures suggest, however, that there are no differences with regards to these aspects between 
the treatment arms. Thus, HRQoL becomes even more important.  
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9 METHODOLOGICAL CONSIDERATIONS 
 
Paper 1: A total of 660 patients were identified via medical files at Radiumhemmet, 
Karolinska. In addition, the patients’ files reviewed in order to exclude patients who relapsed 
or who had died during the time since treatment. Thus, we consider the recruitment procedure 
to be thorough. The response rate was high, indicating that we obtained a representative 
sample. Validated questionnaires used. A cross sectional study procedure was, however used, 
asking about information received during a long period. The results are therefore subjected to 
possible recall bias. In addition, the study-design does not allow the exploration of the 
direction of the associations found between satisfaction with information and HRQoL.  
Paper 2: This randomized study included PC patients in curative intented treatments of RP or 
RT. The study was performed at five centre, and there is a possibility that the treatments 
differed between centre. As the study was randomized, this was not considered a problem, as 
both arms were expected to be affected by this bias to the same extent. On the contrary, 
multicentre including patients, improves generalization of the results, as compared to single 
center studies. Validated questionnaires were used, making comparisons with other studies 
possible. The sample size was, however, a large methodological problem. The accrual rate 
was low, and the study was closed before the estimated sample size was reached. The results 
of the study must therefore be interpreted with caution.  
Paper 3 & 4: The main methodological problem in this randomized study, as in Paper 3, is 
the sample size. An amendement, introducing a new sample calculation based on HRQoL, 
was introduced. The new sample size was estimated to 110 patients. It is therefore not 
possible to calculate OS and TTP in the study. The sample size was, however, sufficient to 
show differences in HRQoL between the two-randomization arms. Validated questionnaires 
were used, and the completion rates for the questionnaires at the assessment points were high. 
Another methodological problem was the measurement of PV by different physicians, 
making a bias due to inter-individual variations possible. Two physicians, however, went 
through all estimations in order to minimize this risk of bias. 
 
10 CLINICAL IMPLICATIONS 
 
Paper 1: Information gained by this study may have great impact in future how we work in 
giving information to our patients with localized prostate cancer. This is because curative 
intent treatments have diverse side effects on urinary, bowel and sexual functions. We have 
found many areas of improvement to discuss at our clinic. Significant differences between 
oncology-and surgery clinic about patient satisfaction with information given at consultations 
found. This indicates that it is important to pay attention to information also to patients who 
have previously gone through RP, although these can be expected to have received thorough 
information earlier. They are, however, in a new situation when they are reffered to RT after 
treatment failure.  
Paper 2: Conclusions about the efficacy of the two treatments in terms of OS and DFS could 
not be obtained due to low power in this study. No discernible differences between the groups 
in HRQoL or complications of treatments were found. The levels of problems reported by the 
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men in both randomization arms at different time points can, however, be conveyed to the 
patients when informing about treatment options. This information about what to expect in 
terms of HRQoL during and after treatment may help men coping with their disease and 
treatment. 
Paper 3 & 4: The results suggest that AA is to be preferred compared to TAB in patients 
with low risk PC in the neoadjuvant setting. The effect on PV of TAB was better, but this 
effect did not appear to affect HRQoL. Thus, the rationale for decreasing the target volume in 
order not to hamper HRQoL not found in this study, further supporting the use of AA. It 
should be kept in mind, however, that OS and DFS could not be evaluated in this mostly 
intermediate-risk group, probably due to a small sample size. Our figures do not, however, 
indicate any negative effect on these parameters during follow-up. 
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11 GENERAL CONCLUSIONS 
 
Based on all four studies included in this thesis, the conclusions made as 
follows: 
 
®  Patients treated with both prostatectomy and salvage RT reported significantly lower 
levels of satisfaction with information received, and of having received significantly less 
information than did patients treated with RT alone in curative setting. The majority 
reported being satisfied with the information received, despite room for improvement 
regarding information about disease, other services, different places of care and things you 
can do to help yourself. 
 
® Open radical prostatectomy and the combined high-dose rate brachytherapy with external 
beam radiation therapy appeared to be comparable in the measured outcomes, as no 
statistically significant differences between the two randomization groups were found for 
any of the HRQoL variables or side effects of treatments. Emotional functioning improved 
over time, social functioning decreased and financial difficulties increased. 
® Antiandrogen in the neoadjuvant setting is possible to be preferred compared to total 
androgen blockade, as higher levels of HRQoL, especially in the sexual domain found. There 
were no between-group differences in PC-specific deaths, PSA progression-free survival, or 
OS. 
® Significantly larger reduction of prostate volume achieved following neoadjuvant total 
androgen blockade compared to antiandrogen. This reduction, however, did not appear to 
translate into a more favourable HRQoL profile of the subsequently given radiation therapy.   
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12 POPULÄRVETENSKAPLIG SAMMANFATTNING  
 
Prostata cancer (PC) är den vanligaste cancerformen hos män i västvärlden. I Sverige 
drabbades 10,985 män under 2014, och den åldersstandardiserade incidensen var 226/100, 
000 (Socialstyrelsen, 2015). Medelåldern är hög vid diagnos, cirka 70 år. Behandling av 
lokaliserad PC är kontroversiell. Radikal prostatektomi (kirurgi) och strålbehandling tillhör 
behandlingsalternativen med botande syfte. Få randomiserade studier har jämfört dessa 
alternativ (Grimm et al, 2012).  Det finns också studier som visat att man kan leva länge även 
utan behandling (Albertsen et al, 2005).  Det är viktigt att man vid behandlingsval diskuterar 
eventuella biverkningar av de olika behandlingarna med patienter, eftersom behandlingarna 
har biverkningsprofiler. Dessa biverkningsprofiler påverkar också den hälso-relaterade 
livskvaliteten på olika sätt (Ellett et al., 2013).  
Studier har visat att många cancerpatienter kan hantera sin sjukdom väl om de får tillräcklig 
och god information.  Dessutom minskar deras rädsla, och oro, samtidigt som den hälso-
relaterade livskvaliteten förbättras (Lerman et al., 1993; Meredith et al., 1996; Thomas et al., 
1999). Om man är nöjd med information mår man bättre, både fysiskt och socialt (Davies et 
al., 2008). Behovet av information kvarstår under hela cancerförloppet och är ett viktigt stöd 
för patienterna (Harrison et al., 2009). De flesta önskar mer information kring sin sjukdom, 
behandlingsalternativ, rehabiliterings möjligheter och uppföljning (Jenkins et al, 2001).  
Hormonbehandling tillsammans med strålbehandling minskar risken för både återfall och död 
i lokalt-avancerad PC (Bria et al, 2009). Neo-adjuvant hormonbehandling används vanligen 
vid intermediär och hög-risk PC inför den kurativt syftande strålbehandlingen. Den vanligaste 
kombinationen är så kallat TAB (Total androgen blockad), vilken är en kombinaion av GnRH 
(Gonadotropin releasing hormone)-analog och en anti-androgen. Användning av enbart anti-
androgen i monoterapi vid lokalt avancerad PC ger ingen signifikant skillnad i 
sjukdomsprogress eller överlevnad jämfört med kastrationsbehandling (Iversen et al, 2000). 
Dessutom, hade patienterna på monoterapi gruppen bättre fysisk- och sexuell förmåga 
jämfört med en kastrationsgrupp som led av svettningar, vallningar, trötthet. Bröstsvullnad 
och ömhet i brösten var dock dominerande i antiandrogen gruppen.  
De flesta PC patienter botas idag och förväntas återgå till ett normalt liv. Det saknas evidens 
vilken av behandlingarna (kirurgi eller strålbehandling) som har den bästa kurativa effekten. 
Hälso-relaterade livskvalitet (HRQoL) är därför en viktig aspekt att beakta vid 
behandlingsval. Eftersom båda behandlingar har biverkningar bör man informera det vid 
möte inför patienten´s behandlingsval. Denna avhandling fokuserar att ta reda på hur nöjda 
PC-patienter är med information dem får och hur denna information påverkar deras HRQoL. 
Vidare studeras HRQoL i samband med kurativt syfte behandling (neoadjuvant hormonell 
behandling, kirurgi och strålbehandling). Slutligen undersöks effekterna på prostatavolym 
och strålbehandlingsfält av två olika neo-adjuvanta hormonbehandlingar. 
 
Syfte, patienter, metod och resultat 
Delarbete 1: Undersöker PC patienters uppfattning av information inför, under och efter 
kurativt syftande strålbehandling, samt deras tillfredställelse med information och kopplingen 
till hälso-relaterade livskvalitet. År 2010 skickades två validerade frågeformulär, EORTC 
QLQ C30 (livskvalitetsfrågor) + EORTC QLQ INFO25 (informationsfrågor) till 660 
patienter med frankerat svarskuvert och information om studien. Svarsfrekvensen var 92 %. 
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Vi fann ett starkt samband mellan livskvalitet och tillfredställelse med informationen. 
Överraskande hade patienter som opererades och därefter strålbehandlades (salvage RT)     
pga PSA-återfall fått mindre information än de som fick strålbehandling som första 
behandlingsalternativ. Det finns ett utrymme för förbättring när det gäller vissa 
informationsområden. 
Delarbete 2: Skillnader mellan kirurgi (RP) och strålbehandling (RT) vid kurativt syftande 
behandling studerades hos 89 patienter vid tre mätningstillfällen, vid randomisering, samt 12 
månader och 24 månader efter behandling. Två frågeformulär användes, EORTC-QLQ C33 
(livskvalitetsfrågor) och EORTC QLQ PR25 (symtomfrågor). Ingen signifikant skillnad 
noterades mellan behandlingarna avseende livskvalitet. Emotionell funktion förbättrades över 
tid i båda grupperna, medan social funktion minskade och ekonomiska svårigheter pga 
sjukdom och behandling ökade. Urininkontinens ökade i den grupp som genomgått kirurgi. 
Den strålbehandlade gruppen hade mer besvär med avföringsinkontinens efter två år.  
Impotens var ett vanligt problem i båda grupperna vid denna tidpunkt. Eftersom 
studiegruppen var liten kunde inga slutsatser avseende behandlingarnas kliniska effekter dras.  
Delarbete 3: Studerade primärt livskvalitet hos PC-patienter med framför allt intermediär-
risk, randomiserades mellan total androgen blockad och anti-androgen behandling. Totalt 110 
patienter deltog (55 i vardera gruppen). Livskvalitet mättes vid sex tillfällen med EORTC 
QLQ-C30 och EORTC-PR25 (före randomisering och 3, 9, 12, 15, 18 månader efter). De 
som behandlats med anti-androgen hade större sexuellt intresse, bättre livskvalitet, och 
mindre vattenkastningsproblem och fatigue efter tre månader. Vid 18-månadersmätningen 
kvarstod endast skillnaden i sexuellt intresse. Patienter i anti-androgengruppen hade också 
bättre kognitiv funktion vid detta mättillfälle. I genomsnitt följdes patienterna upp i 6,9 år. 
Under den tiden avled två patienter av PC, en i vardera gruppen. Återfall i PC noterades hos 
totalt tolv patienter (åtta i antiandrogen; fyra i TAB. Sex patienter avled av andra orsaker 
(fyra i anti-androgen; två i TAB). Inga statistiskt signifikanta skillnader uppmättes mellan 
behandlingarna avseende total överlevnad eller PSA progression-fri överlevnad. 
Delarbete 4: Patienterna var de samma som i delarbete 3. Syftet med studien var att jämföra 
förändringar i prostatavolym i de båda randomiseringsgrupperna, samt också att undersöka 
skillnader i storleken på planerade strålfält. Elva patienter som behandlades med enbart 
extern strålterapi kunde inte analyseras, eftersom volym före behandling inte mätts på dem. 
Det saknades också information om prostatavolym för ytterligare elva patienter vid 
studiestart. Totalt analyserades 88-patienters prostatavolym. I TAB gruppen minskade 
prostatavolymen mer än i anti-androgengruppen. Överraskande nog ökade volymen hos fem 
patienter (fyra i anti-androgen-grupp och en i TAB-grupp). Strålfälten blev mindre i TAB 
gruppen jämfört med anti-androgengruppen .  
Slutsatser 
Även om patienterna huvudsakligen var nöjda med den information de fått finns utrymme för 
förbättring. Patienter som var missnöjda med informationen hade sämre livskvalitet. De som 
genomgick strålbehandling på grund av PSA-återfall efter kirurgi, var inte lika nöjda med 
informationen jämfört med de som fick strålbehandling som första alternativ. 
I den randomiserade studien där kirurgi och strålbehandling jämfördes fann vi inga skillnader 
i livskvalitet mellan behandlingarna. Eftersom studien avbröts i förtid, var studiegruppen för 
liten för att kunna utvärdera de kliniska effekter av behandlingarna.  
Antiandrogen tycktes bättre än totalt androgen blockad avseende sexuellt intresse- och 
funktion, fatigue, vattenkastningsproblem och livskvalitet före start av strålbehandling. 
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Effekten på sexuellt intresse kvarstod vid 18-månaders mätning, då vi också fann en bättre 
kognitiv funktion i anti-androgengruppen. Ytterligare studier behövs dock för att avgöra om 
total androgen blockad är bättre avseende minskad risk för mikrometastaser jämfört med anti-
androgen. Total androgen blockad minskade prostata-volym mer än anti-androgen 
behandling, vilket också påverkade storleken på strålfälten. Detta översattes dock inte i bättre 
livskvalitet i den grupp som behandlats med total androgen blockad.   
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